• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用快速高效的液-液萃取和固相萃取法测定血浆中[18F]FCWAY、[18F]FP-TZTP及其代谢物。

Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions.

作者信息

Ma Ying, Kiesewetter Dale O, Lang Lixin, Der Margaret, Huang Bill, Carson Richard E, Eckelman William C

机构信息

PET Department, The Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA.

出版信息

Nucl Med Biol. 2003 Apr;30(3):233-40. doi: 10.1016/s0969-8051(02)00452-3.

DOI:10.1016/s0969-8051(02)00452-3
PMID:12745014
Abstract

Liquid-liquid and solid phase extraction methods were developed for the accurate and rapid quantitation of radioactive components in human plasma following injection of two PET ligands. A solid phase extraction (SPE) method was developed for the determination of the 5HT(1A) receptor ligand [N-[2-[4-(2-methoxyphenyl) piperazino]ethyl]-N-(2-pyridinyl) trans-4-[(18)F]fluorocyclohexanecarboxamide (FCWAY), and its acidic metabolite, 4-[(18)F]fluorocyclohexane carboxylic acid (FC). In both cases, the extraction method was much faster and easier to use, yet provided results comparable to HPLC and TLC methods. In addition, an easy to perform two-step liquid-liquid extraction was developed for quantitation of 3-(3-((3-[(18)F]fluoropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine ([(18)F]FP-TZTP), a selective M2 muscarinic agonist.

摘要

开发了液-液萃取和固相萃取方法,用于在注射两种正电子发射断层显像(PET)配体后准确快速地定量人血浆中的放射性成分。开发了一种固相萃取(SPE)方法,用于测定5HT(1A)受体配体[N-[2-[4-(2-甲氧基苯基)哌嗪基]乙基]-N-(2-吡啶基)反式-4-[(18)F]氟环己烷甲酰胺(FCWAY)及其酸性代谢物4-[(18)F]氟环己烷羧酸(FC)。在这两种情况下,萃取方法更快且更易于使用,但其提供的结果与高效液相色谱(HPLC)和薄层色谱(TLC)方法相当。此外,还开发了一种易于操作的两步液-液萃取方法,用于定量3-(3-((3-[(18)F]氟丙基)硫代)-1,2,5-噻二唑-4-基)-1,2,5,6-四氢-1-甲基吡啶([(18)F]FP-TZTP),一种选择性M2毒蕈碱激动剂。

相似文献

1
Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions.使用快速高效的液-液萃取和固相萃取法测定血浆中[18F]FCWAY、[18F]FP-TZTP及其代谢物。
Nucl Med Biol. 2003 Apr;30(3):233-40. doi: 10.1016/s0969-8051(02)00452-3.
2
Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes.人源和大鼠肝细胞产生的18F标记的M2毒蕈碱受体激动剂3-(3-[(3-氟丙基)硫代]-1,2,5-噻二唑-4-基)-1,2,5,6-四氢-1-甲基吡啶的代谢产物鉴定
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 25;766(2):319-29. doi: 10.1016/s0378-4347(01)00517-5.
3
Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice.在M2受体基因敲除小鼠中,毒蕈碱配体[18F]FP-TZTP的脑区摄取显著降低,但在M1、M3和M4受体基因敲除小鼠中未出现这种情况。
Neuropharmacology. 2003 Apr;44(5):653-61. doi: 10.1016/s0028-3908(03)00050-9.
4
Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow.
Synapse. 2003 Nov;50(2):151-63. doi: 10.1002/syn.10257.
5
Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET.用于正电子发射断层显像(PET)成像毒蕈碱M2受体的11C标记TZTP不同类似物的药代动力学比较。
Nucl Med Biol. 2008 Apr;35(3):287-98. doi: 10.1016/j.nucmedbio.2008.01.001.
6
3-(3-(3-[F]Flouropropyl)thio)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine3-(3-(3-[F]氟丙基)硫代)-1,2,5-噻二唑-4-基)-1,2,5,6-四氢-1-甲基吡啶
7
In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines.
Synapse. 1999 Jan;31(1):29-40. doi: 10.1002/(SICI)1098-2396(199901)31:1<29::AID-SYN5>3.0.CO;2-9.
8
The automated radiosynthesis of [18F]FP-TZTP.
Nucl Med Biol. 2003 Jan;30(1):73-7. doi: 10.1016/s0969-8051(02)00354-2.
9
In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers.
Synapse. 2003 Apr;48(1):39-44. doi: 10.1002/syn.10165.
10
An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP.毒蕈碱型M2放射性药物[18F]FP-TZTP的改进放射性合成方法。
Appl Radiat Isot. 2009 Apr;67(4):611-6. doi: 10.1016/j.apradiso.2008.12.015. Epub 2008 Dec 25.

引用本文的文献

1
Plasma radio-metabolite analysis of PET tracers for dynamic PET imaging: TLC and autoradiography.用于动态正电子发射断层显像(PET)成像的PET示踪剂的血浆放射性代谢物分析:薄层层析法(TLC)和放射自显影术。
EJNMMI Res. 2020 Nov 23;10(1):141. doi: 10.1186/s13550-020-00705-2.
2
(18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.(18)F-FCWAY,一种5-羟色胺1A受体放射性配体,是人类血脑屏障处外排转运的底物。
Neuroimage. 2016 Sep;138:134-140. doi: 10.1016/j.neuroimage.2016.05.045. Epub 2016 May 19.
3
First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.
对18F-美法韦(一种特异性针对5-羟色胺-1A受体的正电子发射断层扫描放射性配体)进行的首次人体评估。
J Nucl Med. 2014 Dec;55(12):1973-9. doi: 10.2967/jnumed.114.145151. Epub 2014 Nov 13.
4
Imaging of the muscarinic acetylcholine neuroreceptor in rats with the M2 selective agonist [18F]FP-TZTP.用 M2 选择性激动剂 [18F]FP-TZTP 对大鼠毒蕈碱乙酰胆碱能神经受体进行成像。
Nucl Med Biol. 2012 Jan;39(1):45-55. doi: 10.1016/j.nucmedbio.2011.06.003. Epub 2011 Aug 9.
5
Applications of LC-MS in PET radioligand development and metabolic elucidation.LC-MS 在正电子发射断层显像放射性配体研发和代谢物解析中的应用。
Curr Drug Metab. 2010 Jul;11(6):483-93. doi: 10.2174/138920010791636167.
6
Application of highly sensitive UPLC-MS to determine biodistribution at tracer doses: validation with the 5-HT1A ligand [(18)F]FPWAY.应用高灵敏度超高效液相色谱-质谱联用技术测定示踪剂量下的生物分布:以5-HT1A配体[(18)F]FPWAY进行验证
Nucl Med Biol. 2009 May;36(4):389-93. doi: 10.1016/j.nucmedbio.2009.01.002. Epub 2009 Mar 26.
7
An automated one-step one-pot [(18)F]FCWAY synthesis: development and minimization of chemical impurities.自动化一步一锅法[(18)F]FCWAY合成:化学杂质的产生与最小化
Nucl Med Biol. 2007 May;34(4):433-8. doi: 10.1016/j.nucmedbio.2007.03.001.